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A 56-year-old male patient with a rare dermatofibrosarcoma protuberans and fibrosarcomatous change (DFSP-
FS) presented with a solitary fluorodeoxyglucose 
(FDG)-avid tumour with no evidence of metastasis 
in the left upper extremity [Figure 1A]. This initial 
presentation was treated with wide excision, 
and then again at its recurrence 8 months later. 
At admission, the patient had symptoms of 
gastritis and underwent an oesophago-gastro-
duodenoscopy, which was normal. Almost 3 years 
after the initial presentation, the patient presented 
with a retroperitoneal mass measuring 1.4 x 0.8 
cm. Investigation revealed the tumour, which was 
avid on FDG-PET/CT (standardised uptake value 
[SUV] max 11.3) and new compared to the previous 
study [Figure 2B]. Mild FDG uptake was also noted 
in a new pulmonary nodule (SUV max 1.9) and 
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INTERESTING MEDICAL IMAGE
Figure 1: Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) scans at the 
same trans-axial levels, showing mildly FDG-avid local recurrence in the shoulder (A), with no lesion subsequently 
identified in the same region (B).
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appeared malignant [Figure 3B]. Figure 4 shows 
the maximum intensity projection (MIP) images 
from the two studies. The retroperitoneal tumour 
was found to be dermatofibrosarcoma protuberans 
with extensive fibrosarcomatous transformation, 
histology grade 3 [Figures 5A and 5B].
DFSP is a rare cutaneous tumour of low 
malignant grade characterised by a pattern of slow, 
infiltrative growth and a marked tendency to recur 
locally after surgical excision.1 DFSP is commonly 
found on the trunk (42–72%), occasionally in the 
proximal extremities (16–30%), and infrequently 
above the neck (10–16%).7 Rare distant metastases 
(in less than 5% of cases) may occur many years 
after the onset of disease and are limited mostly to 
the lungs, followed by regional lymph nodes, while 
the visceral organs and bones are rarely affected.2 
Metastases are more likely with repeated incomplete 
surgical excisions and by tumour de-differentiation 
to higher grades.6 Metastases are associated with 
local recurrence and poor prognosis. The 5-year 
survival rate is estimated at 99.2%.7
DFSP is a fibrosarcoma originating from 
dermal fibroblasts.6 The genetic abnormalities in 
DFSP include a supernumerary ring chromosome 
related to the low amplification of sequences of 
chromosomes 17 and 22 which is a form of balanced 
reciprocal translocation.8 This rearrangement will 
cause fusion of alpha chain type A (COL1A1) 
located on 17q22 to the platelet-derived growth 
factor beta (PDGFB) located on 22q13. As a result, 
the COL1A1-PDGFB gene formation will result in 
up regulation of PDGFB expression, resulting in 
continuous autocrine activation of PDGF receptor 
beta (PDGFR-B) and propagation of the mitotic 
signal by formation of autocrine and paracrine 
loops.9 These transformed cells are inhibited by the 
tyrosine kinase inhibitor imatinib mesylate with 
Figure 2: Fluorodeoxyglucose (FDG) positron emission tomography (PET)/ computed tomography (CT) scan at 
the same trans-axial level comparing the two scans at the time of local recurrence in 2006, when there was no retro-
peritoneal lesion (A) and subsequently at the time of 1.4 x 0.8 cm heterogeneous, left retro-peritoneal distant metastasis 
in 2009 (B).
Figure 3: Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) scan at the 
same trans-axial level comparing the two scans at the time of local recurrence in 2006 when there was no pulmonary 
lesion (A) and subsequently at the time of retro-peritoneal distant metastasis in 2009, when a mildly FDG-avid pulmonary 
nodule was detected (B).
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reported cases of response often documented with 
FDG.10
The surgical objective in DFSP is complete 
tumour excision with maximal normal tissue 
preservation. Hence, a wide local excision with 
lateral margins of at least 3 cm and including the 
underlying fascia is recommended. In addition, 
micrographic controlled excision (MCE) showed 
favourable outcomes in treating DFSP.6 FDG-
PET/CT findings in a case of recurrence of 
dermatofibrosarcoma in the surgical scar have been 
reported.3
FDG-PET/CT has also been used to monitor 
response to imatinib mesylate in 2 reported cases 
of unresectable metastatic DFSP, with a decrease in 
tumour uptake of FDG after treatment documented 
in both cases.4–5 In the former case, this decrease in 
uptake coincided with clinical improvement as early 
as 2 weeks after commencement of the therapy. 4 
In contrast to our case, where a FDG-avid 
pulmonary lesion was noted on PET/CT, a previous 
case reported a pulmonary nodule which was noted 
on CT but not on FDG-PET. It was thought this may 
have been due to the size (8 mm). A case has also 
been reported where DFSP response to imatinib 
was noted on FDG-PET but not on CT.10 This is 
similar to findings in other malignancies. 
DFSP is a rare cutaneous tumour of low 
malignant grade. FDG-PET/CT has been reported 
to be useful in DFSP imaging for delineating disease 
extent, both in staging and recurrence, which 
can be useful in planning surgery. FDG has also 
been documented as assessing DFSP response 
to imatinib, showing response when none was 
noted on CT. Given the rarity of the disease there 
are no large studies to date but the existing data 
appears promising. We suggest that FDG PET/CT 
be considered as an important component of the 
treatment plan of patients with DFSP.
Figure 4: Maximum intensity projection of the fluorodeoxyglucose (FDG) positron emission tomography (PET)/
computed tomography (CT) scans at the time of the first presentation in 2006 with (A) a mildly FDG-avid local recurrence, 
and (B) subsequently, in 2009, with an intensely FDG-avid retro-peritoneal metastasis.
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Figure 5: (A) Pathology slide of low-powered view of fibrosarcoma with herring-bone pattern; (B) Pathology slide 
showing areas of viable tumor fascicles with adjacent necrosis
